Asieris Pharmaceutical Technologies

Asieris Pharmaceuticals is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative drugs and integrated solutions for genitourinary tumors and related diseases. The company's lead product candidates include Vesitrasertib (APL-1202), an oral MetAP2 inhibitor in Phase 3 trials for non-muscle invasive bladder cancer, and Cevira (APL-1702), a photodynamic therapy for cervical high-grade squamous intraepithelial lesions. Asieris aims to bridge the gap between diagnosis and treatment by offering a comprehensive portfolio that includes imaging agents and therapeutic devices. Headquartered in Shanghai with operations in the United States, the company is listed on the Shanghai Stock Exchange STAR Market. Their strategy emphasizes both internal R&D and strategic global partnerships to address unmet medical needs in urology and gynecology. The company is uniquely positioned as a leader in the diagnosis-to-treatment paradigm within the genitourinary specialty.